Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Core Points - Evaxion A/S, a clinical-stage TechBio company, will provide a business update and report its Q3 2025 financial results on November 6, 2025 [1] - The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST, which is open to the public [2] - Evaxion specializes in developing AI-Immunology™ powered vaccines, focusing on immunotherapies for cancer, bacterial diseases, and viral infections [4] Company Overview - Evaxion A/S utilizes its proprietary AI platform, AI-Immunology™, to decode the human immune system and develop novel immunotherapies [4] - The company has a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline targeting bacterial and viral diseases with high unmet medical needs [4] - Evaxion aims to transform patients' lives by providing innovative and targeted treatment options [4]